Research Driven Investing (RDI) has initiated coverage on Corbus Pharmaceuticals Holdings, Inc. (CRBP) with a Neutral rating. Corbus Pharmaceuticals late-stage stage clinical pharmaceutical company that is focused on the development and commercialization of unique medicines aimed at treating inflammatory and fibrotic diseases. Based in Norwood, Massachusetts, the company’s lead product is JBT-101, an oral endocannabinoid-mimetic […]